Kobayashi Pharmaceutical Co (4967) Price & Analysis

Compare

0 Followers

4967 Stock Chart & Stats

Day’s Range― - ―

52-Week Range¥4,850.00 - ¥6,350.00

Previous CloseN/A

Volume384.70K

Average Volume (3M)329.46K

Market Cap

¥390.25B

Enterprise Value¥352.71B

Total Cash (Recent Filing)¥65.75B

Total Debt (Recent Filing)¥846.00M

Price to Earnings (P/E)36.5

Beta0.31

Next Earnings

Jul 31, 2025

EPS Estimate

24.03

Last Dividend Ex-Date

Jun 27, 2025

Dividend Yield1.67%

Share Statistics

EPS (TTM)21.86

Shares Outstanding78,050,000

10 Day Avg. Volume352,970

30 Day Avg. Volume329,456

Financial Highlights & Ratios

PEG Ratio5.87

Price to Book (P/B)1.96

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

¥5,096.79

Price Target Upside-5.49% Downside

Rating ConsensusHold

Number of Analyst Covering1

Kobayashi Pharmaceutical Co News

PremiumCompany Announcements

Kobayashi Pharmaceutical Reports Mixed Q1 2025 Results

2M ago

PremiumPre-Earnings

KBYPF Earnings this Week: How Will it Perform?

2M ago

PremiumCompany Announcements

Kobayashi Pharmaceutical Reports Decline Amidst Product Recall

5M ago

PremiumPre-Earnings

KBYPF Earnings Report this Week: Is It a Buy, Ahead of Earnings?

5M ago

PremiumThe Fly

Kobayashi Pharmaceutical upgraded to Hold from Underperform at Jefferies

8M ago

PremiumCompany Announcements

Kobayashi Pharmaceutical Reports Challenging Third Quarter

8M ago

PremiumPre-Earnings

Is KBYPF a Buy, Before Earnings?

8M ago

PremiumThe Fly

Kobayashi Pharmaceutical initiated with an Underperform at Jefferies

1y ago

See All JP:4967 News

See All News >

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

2.36%

Mutual Funds

― Other Institutional Investors

93.26% Public Companies and

Individual Investors

Detailed Ownership Overview >

4967 FAQ

What was Kobayashi Pharmaceutical Co ’s price range in the past 12 months?

Kobayashi Pharmaceutical Co lowest stock price was ¥4850.00 and its highest was ¥6350.00 in the past 12 months.

What is Kobayashi Pharmaceutical Co ’s market cap?

Kobayashi Pharmaceutical Co ’s market cap is ¥390.25B.

When is Kobayashi Pharmaceutical Co ’s upcoming earnings report date?

Kobayashi Pharmaceutical Co ’s upcoming earnings report date is Jul 31, 2025 which is in 24 days.

How were Kobayashi Pharmaceutical Co ’s earnings last quarter?

Kobayashi Pharmaceutical Co released its earnings results on May 09, 2025. The company reported ¥21.86 earnings per share for the quarter, missing the consensus estimate of ¥50.023 by -¥28.163.

Is Kobayashi Pharmaceutical Co overvalued?

According to Wall Street analysts Kobayashi Pharmaceutical Co ’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Kobayashi Pharmaceutical Co pay dividends?

Kobayashi Pharmaceutical Co pays a Semiannually dividend of ¥44 which represents an annual dividend yield of 1.67%. See more information on Kobayashi Pharmaceutical Co dividends here

What is Kobayashi Pharmaceutical Co ’s EPS estimate?

Kobayashi Pharmaceutical Co ’s EPS estimate is 24.03.

How many shares outstanding does Kobayashi Pharmaceutical Co have?

Kobayashi Pharmaceutical Co has 78,050,000 shares outstanding.

What happened to Kobayashi Pharmaceutical Co ’s price movement after its last earnings report?

Kobayashi Pharmaceutical Co reported an EPS of ¥21.86 in its last earnings report, missing expectations of ¥50.023. Following the earnings report the stock price went down -0.84%.

Which hedge fund is a major shareholder of Kobayashi Pharmaceutical Co ?

Currently, no hedge funds are holding shares in JP:4967

Company Description

Kobayashi Pharmaceutical Co

Kobayashi Pharmaceutical Co., Ltd. (TSE: 4967) is a leading Japanese company specializing in the development, manufacturing, and marketing of consumer healthcare products, pharmaceuticals, and medical devices. Established in 1919, the company operates in several sectors including over-the-counter (OTC) health products, household products, and medical devices. Kobayashi Pharmaceutical is renowned for its innovative approach to product development, with a diverse portfolio that includes pain relief products, gastrointestinal medications, sanitary products, and home care solutions.

4967 Stock 12 Month Forecast

Average Price Target

¥5,096.79

▼(-5.49%Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4843":"¥4,843","5732":"¥5,732","6621":"¥6,621","5287.5":"¥5,287.5","6176.5":"¥6,176.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5096.7928345824,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥5.10K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5096.7928345824,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥5.10K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5096.7928345824,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥5.10K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4843,5287.5,5732,6176.5,6621],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Jul<br/>2024","9":"Sep<br/>2024","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5246.205,5234.711756506338,5223.218513012677,5211.7252695190155,5200.232026025354,5188.738782531693,5177.245539038031,5165.752295544369,5154.259052050707,5142.7658085570465,5131.272565063385,5119.779321569723,5108.286078076062,{"y":5096.7928345824,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5246.205,5234.711756506338,5223.218513012677,5211.7252695190155,5200.232026025354,5188.738782531693,5177.245539038031,5165.752295544369,5154.259052050707,5142.7658085570465,5131.272565063385,5119.779321569723,5108.286078076062,{"y":5096.7928345824,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5246.205,5234.711756506338,5223.218513012677,5211.7252695190155,5200.232026025354,5188.738782531693,5177.245539038031,5165.752295544369,5154.259052050707,5142.7658085570465,5131.272565063385,5119.779321569723,5108.286078076062,{"y":5096.7928345824,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6620.046,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6556.673,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5832.27,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4844.626,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5284.337,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5293.112,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5206.87,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5800.257,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5466.231,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5466.231,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5432.829,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5455.498,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5246.205,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >